Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

5.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.660
Bid (Size) 5.070 (1)
Ask (Size) 6.300 (4)
Prev. Close 5.660
Today's Range 5.660 - 5.660
52wk Range 2.500 - 11.69
Shares Outstanding 124,071,555
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
  
Via Benzinga
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire

Performance

YTD
-35.97%
-35.97%
1 Month
+48.17%
+48.17%
3 Month
+65.98%
+65.98%
6 Month
-31.23%
-31.23%
1 Year
-10.16%
-10.16%

More News

Read More
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Recap: Seres Therapeutics Q2 Earnings
Via Benzinga
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug
Via Benzinga
Recap: Seres Therapeutics Q1 Earnings
Via Benzinga
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Earnings Preview: Seres Therapeutics
Via Benzinga
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Why Is Pinterest Higher By 14%? 20 Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Via Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Via Benzinga
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
From Seres Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
79 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Preview: Seres Therapeutics's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.